Literature DB >> 11290551

Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer.

I Meinhold-Heerlein1, F Stenner-Liewen, H Liewen, S Kitada, M Krajewska, S Krajewski, J M Zapata, A Monks, D A Scudiero, T Bauknecht, J C Reed.   

Abstract

Fas-associated phosphatase-1 (FAP-1) is a protein-tyrosine phosphatase that binds the cytosolic tail of Fas (Apo1, CD95), presumably regulating Fas-induced apoptosis. Elevations of FAP-1 protein levels in some tumor cell lines have been correlated with resistance to Fas-induced apoptosis. To explore the expression of FAP-1 in ovarian cancer cell lines and archival tumor specimens, mouse monoclonal and rabbit polyclonal antibodies were generated against a FAP-1 peptide and recombinant FAP-1 protein. These antibodies were used for immunoblotting, immunohistochemistry, and flow-cytometry analysis of FAP-1 expression in the Fas-sensitive ovarian cancer lines HEY and BG-1, and in the Fas-resistant lines OVCAR-3 FR and SK-OV-3. All methods demonstrated high levels of FAP-1 in the resistant lines OVCAR-3 FR and SK-OV-3, but not in the Fas-sensitive lines HEY and BG-1. Furthermore, levels of FAP-1 protein also correlated with the amounts of FAP-1 mRNA, as determined by reverse transcriptase-polymerase chain reaction analysis. FAP-1 protein levels were investigated by immunoblotting in the National Cancer Institute's panel of 60 human tumor cell lines. Although FAP-1 failed to correlate with Fas-resistance across the entire tumor panel, Fas-resistance correlated significantly with FAP-1 expression (P: < or = 0.05) and a low Fas/FAP-1 ratio (P: < or = 0.028) in ovarian cancer cell lines. FAP-1 expression was also evaluated in 95 archival ovarian cancer specimens using tissue-microarray technology. FAP-1 was expressed in nearly all tumors, regardless of histological type or grade, stage, patient age, response to chemotherapy, or patient survival. We conclude that FAP-1 correlates significantly with Fas resistance in ovarian cancer cell lines and is commonly expressed in ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290551      PMCID: PMC1891890          DOI: 10.1016/S0002-9440(10)64084-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  40 in total

1.  Thymineless death in colon carcinoma cells is mediated via fas signaling.

Authors:  J A Houghton; F G Harwood; D M Tillman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

2.  KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene.

Authors:  G S Wu; T F Burns; E R McDonald; W Jiang; R Meng; I D Krantz; G Kao; D D Gan; J Y Zhou; R Muschel; S R Hamilton; N B Spinner; S Markowitz; G Wu; W S el-Deiry
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

3.  Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.

Authors:  H Ungefroren; M Voss; M Jansen; C Roeder; D Henne-Bruns; B Kremer; H Kalthoff
Journal:  Cancer Res       Date:  1998-04-15       Impact factor: 12.701

4.  No evidence for involvement of mouse protein-tyrosine phosphatase-BAS-like Fas-associated phosphatase-1 in Fas-mediated apoptosis.

Authors:  E Cuppen; S Nagata; B Wieringa; W Hendriks
Journal:  J Biol Chem       Date:  1997-11-28       Impact factor: 5.157

5.  Expression of FAP-1 (Fas-associated phosphatase) and resistance to Fas-mediated apoptosis in T cell lines derived from human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients.

Authors:  M Arai; M Kannagi; M Matsuoka; T Sato; N Yamamoto; M Fujii
Journal:  AIDS Res Hum Retroviruses       Date:  1998-02-10       Impact factor: 2.205

6.  Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions.

Authors:  C M Eischen; T J Kottke; L M Martins; G S Basi; J S Tung; W C Earnshaw; P J Leibson; S H Kaufmann
Journal:  Blood       Date:  1997-08-01       Impact factor: 22.113

7.  Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumor stage.

Authors:  T E Hedlund; R C Duke; M S Schleicher; G J Miller
Journal:  Prostate       Date:  1998-07-01       Impact factor: 4.104

8.  Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system.

Authors:  A J McGahon; A P Costa Pereira; L Daly; T G Cotter
Journal:  Br J Haematol       Date:  1998-06       Impact factor: 6.998

9.  Tissue microarrays for high-throughput molecular profiling of tumor specimens.

Authors:  J Kononen; L Bubendorf; A Kallioniemi; M Bärlund; P Schraml; S Leighton; J Torhorst; M J Mihatsch; G Sauter; O P Kallioniemi
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

10.  Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis.

Authors:  X Zhang; T Brunner; L Carter; R W Dutton; P Rogers; L Bradley; T Sato; J C Reed; D Green; S L Swain
Journal:  J Exp Med       Date:  1997-05-19       Impact factor: 14.307

View more
  25 in total

Review 1.  Role of protein tyrosine phosphatases in cancer.

Authors:  Tasneem Motiwala; Samson T Jacob
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

2.  Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis.

Authors:  Vladimir N Ivanov; Ze'ev Ronai; Tom K Hei
Journal:  J Biol Chem       Date:  2005-11-23       Impact factor: 5.157

3.  miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1.

Authors:  Robert Schickel; Sun-Mi Park; Andrea E Murmann; Marcus E Peter
Journal:  Mol Cell       Date:  2010-06-25       Impact factor: 17.970

4.  FAS associated phosphatase (FAP-1) blocks apoptosis of astrocytomas through dephosphorylation of FAS.

Authors:  Erik D Foehr; Gustavo Lorente; Valerie Vincent; Karoly Nikolich; Roman Urfer
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

5.  Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells.

Authors:  Yashin Sreenivasan; Pongali B Raghavendra; Sunil K Manna
Journal:  J Clin Immunol       Date:  2006-06-16       Impact factor: 8.317

Review 6.  PTPN13/PTPL1: an important regulator of tumor aggressiveness.

Authors:  Gilles Freiss; Dany Chalbos
Journal:  Anticancer Agents Med Chem       Date:  2011-01       Impact factor: 2.505

7.  Differential expression of Fas family members and Bcl-2 family members in benign versus malignant epithelial ovarian cancer (EOC) in North Indian population.

Authors:  Parvesh Chaudhry; Radhika Srinivasan; Firuza D Patel
Journal:  Mol Cell Biochem       Date:  2012-06-12       Impact factor: 3.396

8.  Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.

Authors:  Dirk Bauerschlag; Karen Bräutigam; Roland Moll; Jalid Sehouli; Alexander Mustea; Darius Salehin; Maryla Krajewska; John C Reed; Nicolai Maass; Garret M Hampton; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2012-10-23       Impact factor: 4.553

9.  FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface.

Authors:  Vladimir N Ivanov; Pablo Lopez Bergami; Gabriel Maulit; Taka-Aki Sato; David Sassoon; Ze'ev Ronai
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

10.  Genetic polymorphisms in the PTPN13 gene and risk of squamous cell carcinoma of head and neck.

Authors:  Jiangong Niu; Yu-Jing Huang; Li-E Wang; Erich M Sturgis; Qingyi Wei
Journal:  Carcinogenesis       Date:  2009-12       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.